News: Press Releases

Fougera Announces Approval Of Mometasone Furoate Cream And Ointment (Rx)

MELVILLE, N.Y. ― April 11, 2005 ―Fougera, the leading specialty pharmaceutical manufacturer, today announced it has received approval from the FDA for Mometasone Furoate cream and ointment USP 0.1% (Rx). The product is generically equivalent to Elocon® by Schering. Mometasone Furoate cream and ointment USP 0.1% will be available in 15 g and 45 g tubes. (See product package insert for full prescribing information.)

“By receiving approval for the Mometasone Furoate line of products, Fougera brings to market yet another quality topical to fill an important need,” said David Klaum, Vice President of Sales and Marketing. “Fougera’s ability to offer a continuous stream of new products offers significant benefits to health care providers seeking multi-source alternatives with the ability to reduce health care costs.”

The foremost specialty manufacturer of topical steroids, antibiotics, antifungal and ophthalmic products, Fougera has received more topical generic FDA approvals than any other company over the past six years. Fougera’s ability to offer a continuing flow of new products benefit health care providers seeking a multi-source alternatives.

Founded in 1849 Fougera, a division of ALTANA Inc, is a leading manufacturer of a wide array of generic, multi-source topical and ophthalmic pharmaceuticals in prescription and over-the-counter forms. A top supplier to hospitals and pharmacies, Fougera has received more FDA approvals for topical products than any other company over the past six years. For more information, or to see a preview of new products, please visit: www.fougera.com.